Glenmark Life Sciences IPO - An R&D Driven Active Pharmaceutical Ingredient Player: Geojit
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Geojit Research's IPO Report
Glenmark Life Sciences Ltd., a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., is a leading developer and manufacturer of select high value, non-commoditised active pharmaceutical ingredients in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management and diabetes.
As of March 31, 2021, they had a portfolio of 120 molecules and are adding on average eight to 10 new molecules annually.
They are also providing contract development and manufacturing operations services to pharmaceutical companies.
China plus one strategy by global formulation makers to de-risk their procurement strategies led to a spike in demand for APIs is good for companies like Glenmark Life Sciences.
Click on the attachment to read the full IPO report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.